Consun Pharmaceutical (1681 HK)

Analysis

Health Care • China

Consun Pharmaceutical Group is a modern pharmaceutical enterprise engaged in the research, development, production, and marketing of modern Chinese medicines and medical imaging contrast mediums. It also manufactures and sells traditional Chinese medicines. Key products include Uremic Clearance Granule for kidney disease, Gadopentetate Dimeglumine Injection as a medical contrast medium, and Iron Dextran Oral Solution. The company was founded in 1997 and is headquartered in Guangzhou, China.

Refresh

Exchange Announcement • 24 Sep 2026 06:19

Notification Letter To Non-Registered Shareholders And Reply Form

Exchange Announcement • 24 Sep 2026 06:17

Notification Letter To Registered Shareholders And Reply Form

Exchange Announcement • 24 Sep 2026 06:16

Interim Report 2026

Exchange Announcement • 17 Sep 2026 18:22

Next Day Disclosure Return

Exchange Announcement • 16 Sep 2026 20:20

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00